Lara C. Pullen, PhD, is a medical writer with a PhD in microbiology/immunology from Northwestern University’s Feinberg School of Medicine. As a medical writer she has covered topics as diverse as diabetes, cardiovascular disease, and autism. Her favorite subject, however, is the role of the immune system in health and disease. Dr. Pullen is also the mother of three children, the youngest of whom has Prader-Willi Syndrome (PWS). She is an active member of the PWS community and a thought leader on the importance of the ketogenic diet for this patient population.
A recent study in nurses and healthcare professionals examined the efficacy of a novel ergonomic aid for managing low back pain. After a three-month trial, researchers found that the aid, Spinal Underwear, reduced low back pain, suggesting that musculoskeletal symptoms may be influenced by posture and somatization…
Stimulation with both Kveim reagent and vimentin induces a specific pro-inflammatory cytokine secretion from sarcoidosis PBMCs. Further investigation may identify novel biomarkers to assist the diagnosis of sarcoidosis…
Research has identified a subset of T cells, peripheral helper (TPH) cells, which may promote pathological B cell responses and antibody production in patients with seropositive RA. TPH cells also express chemokine receptors, enabling them to infiltrate inflamed parts of the body and stimulate B cells to produce antibodies…
A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…
New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…
A recent observational study found a link between high-intensity statin therapy and a 23% reduced risk of rheumatoid arthritis. Although further research is needed, researchers note this study “provides robust evidence of a protective effect of high-intensity statins on the risk of RA.”
A recent analysis has examined the effectiveness of baricitinib in treating RA patients who suffer from comorbidities and the effect of concomitant use of steroids. Baricitinib proved effective, particularly in patients who had exposure to cDMARDs and corticosteroids…
Recent research examined the relationship between patients with scleroderma who are anti-CTP antibody negative and cancer. Combing two complementary technologies, PhIP-Seq and PLATO-BC, researchers identified the POLR3 complex in cancer-associated scleroderma…
Two previously unidentified cellular players in the pathogenesis of primary Sjogren’s syndrome (pSS) have been discovered: a regulatory T cell (Prdm1+eTreg) and a helper T cell (Il21+Th1). In the study, researchers also identified the transcriptional signatures of these cells and their differential dependency on the lymphotoxin/LIGHT signaling axis, which may guide future therapeutic interventions…
Microparticles in the blood of SLE patients may be a source of extracellular HMGB1, which is involved in immune response. Researchers found that analysis may be able to determine if the patient is producing dead, dying and activated cells that are important for SLE pathogenesis…